Clinical trials: Covid19 Immunology
SARS-CoV2 Infection, Multisystem Inflammatory Syndrome in Children
MISC COVID-19 Study in Pediatric Population
Rationale: Severe Acute Respiratory Syndrome - Coronavirus - 2 (SARS-CoV2) and its related Coronavirus Disease - 19 (COVID-19) has become a health emergency worldwide.
- Trial name
- COVID-19 (NCT04844242)
- Where
- India
- Volunteers
- 180 people
- Sponsor
- Tuberculosis Research Centre, India
HIV-infection/Aids, Coronavirus Infection
COHIVE: Coronavirus (COVID-19) Outcomes in HIV Evaluation in Resource Limited Settings
COHIVE is an observational cohort nested in four antiretroviral therapy research studies (ADVANCE - NCT03122262; D²EFT - NCT03017872; DolPHIN2 - NCT03249181 and NAMSAL-ANRS12313 - NCT02777229).
- Trial name
- NCT04371835
- Where
- 15 sites in Argentina, Brazil and 8 more
- Volunteers
- 596 people
- Sponsor
- Kirby Institute
Nephrotic Syndrome, Focal Segmental Glomerulosclerosis
Predictive Determinants of Nephrotic Syndrome Remission in Patients With At-risk Polymorphism of APOL1
This is a multicentric retrospective observational cohort study. As primary objective, the study aims to evaluate the factors associated with nephrotic syndrome remission in patient with nephrotic syndrome, biopsy-prove minimal…
- Conditions
- Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, APOL1 Associated Kidney Disease
- Trial name
- NEPHROL1 (NCT06443034)
- Where
- France
- Volunteers
- 124 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
COVID-19
Immunosuppression and COVID-19 Boosters
It is important people receiving immunosuppressive therapy are provided with the best protection against COVID-19 because they are at greater risk of severe illness should they become infected.
- Trial name
- NCT05415267
- Testing
- diphtheria and tetanus toxoids (adsorbed) vaccine, COVID-19 vaccine
- Where
- 5 sites in Australia
- Volunteers
- 320 people
- Sponsor
- Kirby Institute
Coronavirus, Coronavirus Infection
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
This study is a Phase 1 / 2 trial to determine the safety and efficacy of CYNK-001, an immunotherapy containing Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded, in patients with moderate…
- Conditions
- Coronavirus, Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2, Pneumonia
- Trial name
- CYNKCOVID (NCT04365101)
- Testing
- CYNK-001
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Celularity Incorporated
Influenza, Human, SARS-CoV-2 Infection
Does Repeat Influenza Vaccination Constrain Influenza Immune Responses and Protection
The objectives of this study are to understand the long-term consequences of repeated annual influenza vaccination among healthcare workers (HCWs) and to use statistical and mathematical modelling to elucidate the immunological…
- Trial name
- NCT05110911
- Testing
- Influenza vaccination: Fluarix Tetra, Vaxigrip Tetra, Fluquadri, Fluad Quad, Afluia Quad, Flucelvax Quad, SARS-CoV-2 vaccination: Comirnaty or Vaxzevria
- Where
- 6 sites in Australia
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- University of Melbourne
Respiratory Tract Infections (RTI), Mucosal Immunity
To Evaluate Mucosal and Systematic Immune Response to Acute Respiratory Tract Infections of South African Children
The goal of this observational study is to answer a few questions about respiratory tract infections in South African children: 1.
- Trial name
- Muco-Kids (NCT06902194)
- Where
- 2 sites in South Africa
- Volunteers
- 250 people
- Sponsor
- Desmond Tutu TB Centre
Covid19, Coronavirus
QuadraMune(TM) for Prevention of COVID-19
QuadraMune(TM) is a nutritional supplement which has previously been demonstrated to possess antiinflammatory and immune modulatory activity based on in vitro and pilot in vivo studies.
- Conditions
- Covid19, Coronavirus, SARS-CoV 2
- Trial name
- NCT04421391
- Testing
- QuadraMune(TM)
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Therapeutic Solutions International
End Stage Kidney Disease
Phenotyping Seroconversion Following Vaccination Against COVID-19 in Patients on Haemodialysis Study
Patients on haemodialysis are at higher risk of getting a severe form of COVID-19 if they become infected. Vaccinations are soon to arrive and offer great hope of controlling the current pandemic.
- Trial name
- NCT04815850
- Where
- United Kingdom
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- University of Leicester
Covid19
Understanding Immunology and Patient Outcomes of COVID-19 in Hospitalized Patients
The adaptive immune response, consisting of antiviral T and B cells, is critical for providing protection against viruses such as SARS-CoV-2, both during an active infection and later following a subsequent exposure.
- Trial name
- NCT04892797
- Testing
- Covid-19+ observational
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Vermont
COVID-19
Serology and Other Immunologic Response Tests in the Diagnosis of COVID-19 in Pediatrics
Despite the SARS-CoV-2 virus being present worldwide, and although it is now clear that children are affected by the disease with milder symptoms than adults, many immunological questions, which are very relevant for Public…
- Trial name
- Covid_IMMUNO (NCT05795790)
- Where
- Italy
- Volunteers
- 249 people
- Sponsor
- IRCCS Burlo Garofolo
Covid19, SARS-CoV-2
Study of the Immunological and Virological Response of Patients With COVID-19 and Presenting an Asymptomatic or Pauci-symptomatic Form (AMBUCOV)
The purpose of this study is to describe the immunological and virological response of patients infected with CoV-2-SARS and presenting an asymptomatic or mildly symptomatic form, in particular the innate and adaptive response as…
- Trial name
- AMBUCOV (NCT04703114)
- Testing
- Blood count, Blood collection, Nasopharyngeal swab
- Where
- France
- Volunteers
- 57 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Infection, Coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2
Host-pathogen Interactions During SARS-CoV-2 Infection
The new Severe acute respiratory syndrome coronavirus (SARS-CoV-2) named coronavirus disease 2019 (COVID-19) is currently responsible for a pandemic spread of febrile respiratory infections, responsible for a veritable global…
- Trial name
- HPI-COVID-19 (NCT04376476)
- Testing
- Blood sample, Low or upper respiratory tract sample, Stool collection or fecal swab
- Where
- 12 sites in France
- Volunteers
- 140 people
- Sponsor
- Hospices Civils de Lyon
Covid19
Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection
It is our hypothesis that a course of Ta1 administered to hospitalized individuals with COVID-19 infection and lymphocytopenia will improve the time to recovery (primary objective) and severity of infection (secondary objectives)…
- Trial name
- Ta1 (NCT04487444)
- Testing
- Thymalfasin
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Rhode Island Hospital
IgM and IgG in Blood
Immune Response Following COVID-19 Vaccination
Few trials have reported the safety and efficacy of the COVID-19 vaccines. However, these trials were mostly focused on post-vaccination adverse events and short-term antibody detection with none monitoring the presence of…
- Trial name
- IFVAC (NCT04736524)
- Testing
- Rapid antibody test
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Texas Cardiac Arrhythmia Research Foundation
Epidemiology, Clinical
Prognostic Factors and Outcomes of COVID-19 Cases in Ethiopia
The aim of the study will be to determine the epidemiological and clinical features of COVID-19 cases, immunological and virological courses, interaction with nutritional status, and response to treatment for COVID-19 patients…
- Conditions
- Epidemiology, Clinical, Nutritional-status, Immunologic Defect
- Trial name
- NCT04584424
- Testing
- The study does not required
- Where
- Ethiopia
- Volunteers
- 6,390 people
- Sponsor
- Ethiopian Public Health Institute
Vaccine Adverse Reaction, Seroconversion
Safety and Immunogenicity of Oxford AstraZeneca Vaccine Against COVID-19 Infection
After SARS-COV-2 inactivated vaccine authorization for use in different countries including Egypt, investigating its immunogenicity, safety, and efficacy in preventing COVID-19 infection is highly needed.
- Trial name
- NCT04756271
- Testing
- SARS-Cov-2 neutralizing antibody titer
- Where
- Egypt
- Volunteers
- 246 people, healthy volunteers welcome
- Sponsor
- Zagazig University
COVID-19
COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)
This phase 2 clinical trial will evaluate the safety and immunogenicity of additional doses of prototype and variant (alone or in combination) vaccine candidates in previously vaccinated participants with or without prior severe…
- Trial name
- NCT05289037
- Testing
- AS03, BNT162b2, BNT162b2 (B.1.1.529)
- Where
- 22 sites in United States
- Volunteers
- 1,270 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Syphilis
Impact of COVID-19 on Provision and Uptake of Prevention of Mother-to-child Transmission of HIV Services in Zimbabwe
The COVID-19 pandemic and response are likely to lead to severe unintended consequences for the prevention of mother-to-child transmission (PMTCT) of HIV and syphilis.
- Trial name
- NCT04782739
- Testing
- None - Descriptive study
- Where
- 2 sites in Zimbabwe
- Volunteers
- 30 people
- Sponsor
- University of Zimbabwe
Covid19, Hiv
Effects of COVID-19 on Endothelium in HIV-Positive Patients in Sub-Saharan Africa
Background: Coronavirus disease 2019 (COVID-19) has affected almost every country in the world, especially in terms of health system capacity and economic burden.
- Conditions
- Covid19, Hiv, ART
- Trial name
- ENDOCOVID (NCT04709302)
- Testing
- COVID-19, HIV, ART
- Where
- 3 sites in Nigeria, South Africa
- Volunteers
- 342 people
- Sponsor
- Medical University of Graz